Kiora Pharmaceuticals
Last updated Jun 20, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
3
Clinical Programs
0
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Ophthalmology
- Retinitis Pigmentosa
Highest priority development: S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (ophthalmology) as Kiora Pharmaceuticals.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 20, 2026Score 16Kiora Pharmaceuticals initiates Phase II trial of KIO-301 for late-stage Retinitis Pigmentosa
Ophthalmology · Retinitis Pigmentosa
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived PharmaceuticalsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Kiora Pharmaceuticals right now?
- Which regulatory precedents should Kiora Pharmaceuticals monitor in Ophthalmology and Retinitis Pigmentosa?
- Which pipeline programs should Kiora Pharmaceuticals prioritize for competitive review?
- What signals require immediate investigation for Kiora Pharmaceuticals?
- Summarize the strategic implications of recent developments for Kiora Pharmaceuticals.
- Where is the greatest uncertainty in Kiora Pharmaceuticals's competitive positioning?